MX2020008569A - Inhibidores selectivos de bcl-2 en combinacion con un anticuerpo anti-pd-1 o anti-pd-l1 para el tratamiento de tipos de cancer. - Google Patents

Inhibidores selectivos de bcl-2 en combinacion con un anticuerpo anti-pd-1 o anti-pd-l1 para el tratamiento de tipos de cancer.

Info

Publication number
MX2020008569A
MX2020008569A MX2020008569A MX2020008569A MX2020008569A MX 2020008569 A MX2020008569 A MX 2020008569A MX 2020008569 A MX2020008569 A MX 2020008569A MX 2020008569 A MX2020008569 A MX 2020008569A MX 2020008569 A MX2020008569 A MX 2020008569A
Authority
MX
Mexico
Prior art keywords
antibody
treatment
combination
cancers
inhibitors
Prior art date
Application number
MX2020008569A
Other languages
English (en)
Inventor
Tamar Uziel
Joel D Leverson
William N Pappano
Haribhai Dipica B Maganbhai
Rebecca Mathew
Fred Kohlhapp
Cherrie K Donawho
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of MX2020008569A publication Critical patent/MX2020008569A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Esta invención se refiere a un método para el tratamiento de cáncer en un sujeto, que comprende administrar al sujeto una cantidad eficaz de un inhibidor selectivo de BCL-2 o un profármaco o una sal aceptable desde el punto de vista farmacéutico de este en combinación con una cantidad eficaz de un anticuerpo anti-PD-1 o un anticuerpo anti-PD-L1.
MX2020008569A 2018-02-16 2019-02-15 Inhibidores selectivos de bcl-2 en combinacion con un anticuerpo anti-pd-1 o anti-pd-l1 para el tratamiento de tipos de cancer. MX2020008569A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862763106P 2018-02-16 2018-02-16
US201862764850P 2018-08-15 2018-08-15
PCT/US2019/018241 WO2019161221A2 (en) 2018-02-16 2019-02-15 Selective bcl-2 inhibitors in combination with an anti-pd-1 or an anti-pd-l1 antibody for the treatment of cancers

Publications (1)

Publication Number Publication Date
MX2020008569A true MX2020008569A (es) 2020-09-21

Family

ID=65529918

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020008569A MX2020008569A (es) 2018-02-16 2019-02-15 Inhibidores selectivos de bcl-2 en combinacion con un anticuerpo anti-pd-1 o anti-pd-l1 para el tratamiento de tipos de cancer.

Country Status (9)

Country Link
US (1) US20190336496A1 (es)
EP (1) EP3752189A2 (es)
JP (1) JP2021513978A (es)
CN (1) CN112135631A (es)
AU (1) AU2019221672A1 (es)
BR (1) BR112020016551A2 (es)
CA (1) CA3090177A1 (es)
MX (1) MX2020008569A (es)
WO (1) WO2019161221A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021062200A1 (en) * 2019-09-27 2021-04-01 The Regents Of The University Of Colorado, A Body Corporate Enhancing cancer therapy treatment with bh3 mimetics
CN110760517B (zh) * 2019-10-09 2022-04-29 天津大学 拮抗pd-1骆驼抗体类似物ap基因及蛋白和应用
EP4100513A4 (en) * 2020-02-07 2024-03-13 University Health Network Methods for enhancing t cells using venetoclax
WO2022122667A1 (en) 2020-12-07 2022-06-16 Cellestia Biotech Ag Pharmaceutical combinations for treating cancer
EP4008324A1 (en) 2020-12-07 2022-06-08 Cellestia Biotech AG Combinations comprising an inhibitor of an anti-apoptotic protein, such as bcl-2, bcl-xl, bclw or mcl-1, and a notch signaling pathway inhibitor for treating cancer
ES2919898B8 (es) * 2021-01-27 2024-02-02 Fundacion Univ San Antonio Nuevo tratamiento del cáncer colorrectal
CN114573696B (zh) * 2022-03-10 2023-07-25 深圳市元谷生物科技有限公司 一种结合程序性死亡受体1(pd-1)的抗体及其用途
JP2026503565A (ja) * 2023-01-19 2026-01-29 シャンハイ フアオタ バイオファーマシューティカル カンパニー、リミテッド 全身性エリテマトーデスの治療方法
WO2025242835A1 (en) 2024-05-22 2025-11-27 Ose Immunotherapeutics Molecules comprising masking linkers and uses thereof for the treatment of cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
WO2005024636A1 (ja) 2003-09-04 2005-03-17 Hitachi Ulsi Systems Co., Ltd. 半導体装置
WO2005049593A2 (en) 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
JP2011523853A (ja) 2008-06-03 2011-08-25 アボット・ラボラトリーズ 二重可変ドメイン免疫グロブリン及びその使用
CN102448959B (zh) 2009-05-26 2015-06-17 艾伯维巴哈马有限公司 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂
TWI520960B (zh) 2010-05-26 2016-02-11 艾伯維有限公司 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑
FR2986002B1 (fr) 2012-01-24 2014-02-21 Servier Lab Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2018158225A1 (en) * 2017-02-28 2018-09-07 Les Laboratoires Servier Combination of a bcl-2 inhibitor and a mdm2 inhibitor, uses and pharmaceutical compositions thereof

Also Published As

Publication number Publication date
JP2021513978A (ja) 2021-06-03
WO2019161221A3 (en) 2019-11-07
BR112020016551A2 (pt) 2020-12-22
CN112135631A (zh) 2020-12-25
US20190336496A1 (en) 2019-11-07
EP3752189A2 (en) 2020-12-23
CA3090177A1 (en) 2019-08-22
AU2019221672A1 (en) 2020-09-03
WO2019161221A2 (en) 2019-08-22

Similar Documents

Publication Publication Date Title
MX2020008569A (es) Inhibidores selectivos de bcl-2 en combinacion con un anticuerpo anti-pd-1 o anti-pd-l1 para el tratamiento de tipos de cancer.
MX2024009727A (es) Terapias de combinacion.
PH12021500004A1 (en) Pd-1/pd-l1 inhibitors
ZA202007007B (en) Mcl-1 inhibitors
MX2019009772A (es) Anticuerpos anti-pd-1 para el tratamiento del cancer de pulmon.
MX2018014435A (es) Inhibidores de muerte programada 1 (pd-1) ligando de muerte programada (pd-l1) para el tratamiento de cancer.
MX2022001757A (es) Inhibidores de muerte programada 1 (pd-19)/ligando de muerte programada 1 (pd-l1) para el tratamiento de cancer.
MX2019008207A (es) Métodos para tratar el cáncer con anticuerpos anti-pd-1.
PH12019500002B1 (en) Combination comprising ep4 antagonist and immune checkpoint inhibitor
HUE065492T2 (hu) CSF1R inhibitorok felhasználásra rák kezelésében
PH12021552675A1 (en) Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating cancer
MX2018007756A (es) Anticuerpos anti-cd20/anti-cd3 biespecificos para tratar leucemia linfoblastica aguda.
EA201990374A1 (ru) Комбинация антитела против cd20, ингибитора pi3-киназы-дельта и антитела против pd-1 или против pd-l1 для лечения гематологических раков
MX383866B (es) Inhibidores de ezh2 para tratar linfomas.
MX2016014753A (es) Tratamiento de cancer de pulmon con el uso de una combinacion de un anticuerpo de muerte anti-programada 1 (anti-pd-1) y otro agente anti-cancerigeno.
MX2017010595A (es) Métodos, composiciones, y equipos para tratamiento de cáncer.
MX385283B (es) Tratamiento de cáncer usando 2-desoxi-2-fluoro-l-fucosa en combinación con un inhibidor del punto de control.
MX2022006932A (es) Combinaciones de inhibidores de diacilglicerol cinasas (dgk) y antagonistas de puntos de control.
MY188849A (en) Combination therapy of an anti cd20 antibody with a bcl-2 inhibitor and a mdm2 inhibitor
AU2017293423A8 (en) Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer
MX2020012782A (es) Inhibidor de ccr5 para el uso en el tratamiento de cancer.
HK1252514A1 (zh) 包含与抗体组合施予的ido抑制剂的肿瘤治疗剂
PL3953393T3 (pl) Połączenie farmaceutyczne antagonisty ep4 i inhibitorów punktów kontrolnych układu odpornościowego do leczenia nowotworów
MX2020004074A (es) Producto de combinacion para el tratamiento de cancer.
MX2022006179A (es) Derivados macrociclicos de indol como inhibidores de mcl-1.